The GlycoDisplay business model focuses on specific drug programs where glyco-optimized leads are identified in close collaboration with pharmaceutical companies. GlycoDisplay delivers expertise within glycoengineering and the pharma partner adds know-how and capabilities within the disease area, assays and animal models. To discuss partnering opportunities please contact us.
Investors
GlycoDisplay is managed by the founder group and funded by investment from GlycoZyme Aps.
